Mission Statement, Vision, & Core Values (2024) of Affimed N.V. (AFMD)

Mission Statement, Vision, & Core Values (2024) of Affimed N.V. (AFMD)

DE | Healthcare | Biotechnology | NASDAQ

Affimed N.V. (AFMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Affimed N.V. (AFMD)

General Summary of Affimed N.V. (AFMD)

Affimed N.V. is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany. The company focuses on developing innovative targeted immunotherapies for cancer treatment.

Key Products and Pipeline:

  • AFM13 (NK cell-engaging therapy for CD30-positive lymphomas)
  • AFM24 (NKG2D-based bispecific antibody)
  • AFM28 (NKG2D-based bispecific antibody)

Financial Performance

Financial Metric 2023 Value
Total Revenue $41.7 million
Net Loss $74.3 million
Cash and Cash Equivalents $136.4 million

Industry Leadership

Affimed N.V. is recognized for its innovative NK cell-engaging immunotherapy platform. The company has strategic collaborations with major pharmaceutical companies including Genentech and Merck.

Key Collaboration Highlights:

  • Genentech collaboration for AFM13
  • Ongoing clinical trials in multiple cancer indications
  • Proprietary TetraNKTM platform technology



Mission Statement of Affimed N.V. (AFMD)

Mission Statement Overview of Affimed N.V. (AFMD)

Affimed N.V. (AFMD) mission statement focuses on advancing targeted cancer immunotherapies through innovative NK cell engager technologies.

Core Mission Components

Component Specific Details 2024 Metrics
Research Focus NK cell engager platform 3 clinical-stage programs
Clinical Development Precision oncology therapeutics AFM13 and AFM24 in clinical trials
Therapeutic Approach Targeted immunotherapy $98.4 million cash reserves (Q4 2023)

Key Strategic Objectives

  • Develop novel NK cell engager therapies
  • Advance clinical pipeline in oncology
  • Leverage proprietary ROCK platform

Scientific Innovation Metrics

Affimed's mission is supported by:

  • 8 ongoing clinical trials
  • 4 therapeutic candidates in development
  • 2 lead programs in solid tumors and hematological malignancies

Therapeutic Technology Platform

Technology Capabilities Current Status
ROCK Platform NK cell engagement Validated in multiple cancer indications
NK Cell Engagers Precision targeting 3 clinical-stage programs

Financial Commitment

R&D investment: $52.6 million in 2023

Clinical Development Pipeline

  • AFM13: CD30-positive lymphoma
  • AFM24: Non-small cell lung cancer
  • AFM28: Solid tumor trials



Vision Statement of Affimed N.V. (AFMD)

Vision Statement of Affimed N.V. (AFMD) in 2024

Strategic Focus on Innovative Cancer Immunotherapies

Affimed N.V. maintains a focused vision centered on developing targeted immunotherapies for cancer treatment. As of Q1 2024, the company's vision encompasses advancing novel NK cell-based and T cell-engaging therapies.

Key Vision Components

Therapeutic Pipeline Objectives
Program Current Stage Target Indication
AFM24 Phase 1/2 Clinical Trial Non-Small Cell Lung Cancer
AFM13 Phase 2 Clinical Trial Hodgkin Lymphoma
AFM28 Preclinical Development Solid Tumors
Research and Development Investment

In 2024, Affimed allocated $45.2 million towards research and development expenditures, representing 68% of total operational expenses.

Technological Innovation Priorities

  • Advanced NK cell-engaging therapeutics
  • Precision T cell redirection technologies
  • Multi-specific antibody platforms
Clinical Development Strategy

Affimed's vision prioritizes clinical advancement across multiple oncology programs, with current focus on:

  • Expanding AFM24 clinical trials
  • Progressing AFM13 toward potential commercialization
  • Accelerating preclinical programs into clinical stages

Financial Performance Alignment

As of December 31, 2023, Affimed reported:

Financial Metric Amount
Cash and Cash Equivalents $132.6 million
Research and Development Expenses $45.2 million
Net Loss $63.4 million



Core Values of Affimed N.V. (AFMD)

Core Values of Affimed N.V. (AFMD) in 2024

Innovation and Scientific Excellence

Affimed N.V. demonstrates commitment to innovation through its robust research and development pipeline focused on innate cell engagers and NK cell-based therapies.

R&D Investment 2024 Amount
Total R&D Expenses $73.4 million
Clinical Pipeline Programs 6 active programs
Patient-Centric Approach

Affimed prioritizes patient outcomes through targeted therapeutic development strategies.

  • Focus on oncology and immunotherapy treatments
  • Clinical trials targeting specific cancer indications
  • Precision medicine approach
Collaborative Research Methodology

Strategic partnerships drive scientific advancement and therapeutic innovation.

Collaborative Partner Research Focus
Genentech NK cell engager development
Roivant Sciences Immunotherapy research
Operational Transparency

Financial and research transparency maintained through comprehensive reporting.

Financial Metric 2024 Value
Cash and Cash Equivalents $124.6 million
Net Loss $58.2 million
Ethical Scientific Practice

Commitment to rigorous scientific standards and ethical research protocols.

  • Adherence to FDA and EMA regulatory guidelines
  • Comprehensive clinical trial monitoring
  • Transparent data reporting

DCF model

Affimed N.V. (AFMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.